Compare
Indivior Pharmaceuticals, Inc. vs Prestige Consumer Healthcare Inc. vs Acadia Pharmaceuticals Inc vs Alkermes plc.
| Latest fiscal year | Indivior Pharmaceuticals, Inc. INDV | Prestige Consumer Healthcare Inc. PBH | Acadia Pharmaceuticals Inc ACAD | Alkermes plc. ALKS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.24B | $1.09B | $1.07B | $1.48B |
| Revenue growth (YoY) | +4.3% | -4.3% | +11.9% | -5.2% |
| Gross margin | 80.2% | 54.7% | 91.7% (computed) | 86.7% (computed) |
| Operating margin | 21.1% | 28.4% | 9.8% | 17.2% |
| Net margin | 16.9% | 17.5% | 36.5% | 16.4% |
| Net income | $210.00M | $190.30M | $391.00M | $241.66M |
| EPS (Diluted) | $1.64 | $3.91 | $2.30 | $1.43 |
| Operating cash flow | -$27.00M | $257.63M | $109.84M | $520.75M |
| Free cash flow | -$93.00M | $246.45M | $105.15M | $480.33M |
| Cash & equivalents | $195.00M | $63.87M | $177.69M | $388.57M |
| Total assets | $1.20B | $3.49B | $1.56B | $2.49B |
| Total liabilities | $1.30B | $1.61B | $336.81M | $667.70M |
| Shareholders' equity | -$98.00M | $1.89B | $1.23B | $1.82B |
| Return on year-end equity | n/a | 10.1% | 31.9% | 13.3% |
| Shares outstanding | n/a | n/a | 170.31M | 165.61M |
Revenue, most recent five fiscal years
| Fiscal year | Indivior Pharmaceuticals, Inc. | Prestige Consumer Healthcare Inc. | Acadia Pharmaceuticals Inc | Alkermes plc. |
|---|---|---|---|---|
| Latest | $1.24B Ended 2025-12-31 | $1.09B Ended 2026-03-31 | $1.07B Ended 2025-12-31 | $1.48B Ended 2025-12-31 |
| 1 year earlier | $1.19B Ended 2024-12-31 | $1.14B Ended 2025-03-31 | $957.80M Ended 2024-12-31 | $1.56B Ended 2024-12-31 |
| 2 years earlier | $1.09B Ended 2023-12-31 | $1.13B Ended 2024-03-31 | $726.44M Ended 2023-12-31 | $1.66B Ended 2023-12-31 |
| 3 years earlier | $901.00M Ended 2022-12-31 | $1.13B Ended 2023-03-31 | $517.24M Ended 2022-12-31 | $1.11B Ended 2022-12-31 |
| 4 years earlier | n/a | $1.09B Ended 2022-03-31 | $484.14M Ended 2021-12-31 | $1.17B Ended 2021-12-31 |